X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (14) 14
male (14) 14
prostate cancer (14) 14
humans (13) 13
oncology (12) 12
hematology, oncology and palliative medicine (11) 11
metastasis (11) 11
aged (10) 10
cancer (9) 9
care and treatment (9) 9
middle aged (9) 9
survival (8) 8
aged, 80 and over (7) 7
cancer therapies (7) 7
chemotherapy (7) 7
clinical trials (7) 7
abiraterone acetate (6) 6
adult (6) 6
prostatic neoplasms - pathology (6) 6
analysis (5) 5
castration (5) 5
docetaxel (5) 5
double-blind method (5) 5
men (5) 5
patients (5) 5
prognosis (5) 5
survival analysis (5) 5
antigens (4) 4
article (4) 4
medical colleges (4) 4
oncology, experimental (4) 4
prednisone (4) 4
prednisone - administration & dosage (4) 4
prostatic neoplasms - drug therapy (4) 4
prostatic neoplasms, castration-resistant - drug therapy (4) 4
prostatic neoplasms, castration-resistant - mortality (4) 4
research (4) 4
studies (4) 4
treatment outcome (4) 4
androgens (3) 3
antineoplastic combined chemotherapy protocols - therapeutic use (3) 3
biomarkers, tumor - blood (3) 3
cells (3) 3
clinical-trials (3) 3
disease (3) 3
double-blind (3) 3
electronic books (3) 3
follow-up studies (3) 3
kaplan-meier estimate (3) 3
neoplasm staging (3) 3
orchiectomy (3) 3
pain (3) 3
placebo (3) 3
prospective studies (3) 3
prostatic neoplasms, castration-resistant - pathology (3) 3
therapy (3) 3
tumors (3) 3
androgen antagonists - therapeutic use (2) 2
antigen (2) 2
antineoplastic agents, hormonal - therapeutic use (2) 2
antitumor-activity (2) 2
asia (2) 2
biomarkers (2) 2
bone neoplasms - secondary (2) 2
cancer patients (2) 2
corticosteroids (2) 2
decision making (2) 2
disease progression (2) 2
disease-free survival (2) 2
dose-response relationship, drug (2) 2
end-points (2) 2
enzalutamide (2) 2
gene (2) 2
inflammation - genetics (2) 2
inflammation - metabolism (2) 2
maximum tolerated dose (2) 2
medical prognosis (2) 2
metastases (2) 2
methods (2) 2
mitoxantrone (2) 2
mitoxantrone plus prednisone (2) 2
mortality (2) 2
neoplasm metastasis (2) 2
open-label (2) 2
patient outcomes (2) 2
peripheral-blood (2) 2
pharmaceutical industry (2) 2
phase-iii (2) 2
phenylthiohydantoin - analogs & derivatives (2) 2
phenylthiohydantoin - therapeutic use (2) 2
physiological aspects (2) 2
progression (2) 2
proportional hazards models (2) 2
prostate (2) 2
prostate-specific antigen - blood (2) 2
prostatic neoplasms - blood (2) 2
prostatic neoplasms - mortality (2) 2
prostatic neoplasms - therapy (2) 2
radiotherapy (2) 2
recommendations (2) 2
more...
Library Location Library Location
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet Oncology, The, ISSN 1470-2045, 2014, Volume 15, Issue 7, pp. 700 - 712
Journal Article
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2014, Volume 15, Issue 10, pp. 1147 - 1156
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2015, Volume 16, Issue 3, pp. 338 - 348
Summary Background Orteronel is an investigational, partially selective inhibitor of CYP 17,20-lyase in the androgen signalling pathway, a validated... 
Hematology, Oncology and Palliative Medicine | MITOXANTRONE | ONCOLOGY | MEN | END-POINTS | ABIRATERONE ACETATE | INCREASED SURVIVAL | DOCETAXEL | ENZALUTAMIDE | Steroid 17-alpha-Hydroxylase - antagonists & inhibitors | Prostatic Neoplasms, Castration-Resistant - enzymology | Humans | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Imidazoles - administration & dosage | Male | North America | Prostatic Neoplasms, Castration-Resistant - pathology | Time Factors | Prednisone - administration & dosage | Double-Blind Method | Europe | Risk Factors | Adenocarcinoma - enzymology | Kaplan-Meier Estimate | Proportional Hazards Models | Treatment Outcome | Prostatic Neoplasms, Castration-Resistant - drug therapy | Adenocarcinoma - drug therapy | Cytochrome P-450 Enzyme Inhibitors - administration & dosage | Adenocarcinoma - secondary | Disease Progression | New Zealand | Disease-Free Survival | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Asia | Naphthalenes - administration & dosage | Intention to Treat Analysis | Aged | Prostatic Neoplasms, Castration-Resistant - mortality | Steroid 17-alpha-Hydroxylase - metabolism | Australia | Adenocarcinoma - mortality | Medical colleges | Care and treatment | Chemotherapy | Corticosteroids | Cytochrome P-450 | Clinical trials | Prednisone | Metastasis | Prostate cancer | Cancer | Steroids
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2012, Volume 13, Issue 12, pp. 1210 - 1217
Journal Article
Lancet, The, ISSN 0140-6736, 2010, Volume 375, Issue 9724, pp. 1437 - 1446
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2017, Volume 18, Issue 1, pp. 132 - 142
Journal Article